<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13239">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00414544</url>
  </required_header>
  <id_info>
    <org_study_id>CosmetaLife 1</org_study_id>
    <nct_id>NCT00414544</nct_id>
  </id_info>
  <brief_title>Evaluation of the Safety and Efficacy of CosmetaLife™ for the Correction of Nasolabial Folds</brief_title>
  <official_title>A Randomized, Double-Blind, Multicenter Comparison of the Safety and Efficacy of CosmetaLife™ Versus Control for the Correction of Nasolabial Folds</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cosmeta</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cosmeta Corp, A Gel-Del Technologies Company</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cosmeta</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind pivotal study to evaluate the safety and effectiveness of
      CosmetaLife injectable dermal filler for the correction of wrinkles and folds, such as
      nasolabial folds (i.e., smile lines).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with negative reaction skin test results will be randomized to receive CosmetaLife
      in one nasolabial fold and Control in the nasolabial fold on the opposite side of the face
      (split face design). Each subject will serve as his or her own control, allowing for
      comparison of the outcome between the contralateral sides. Patients will be followed at 2
      weeks and 3, 6, 9 and 12 months post treatment for assessment of safety and effectiveness.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in Wrinkle Severity Rating Scale</measure>
    <time_frame>baseline and 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To determine if the mean change in the 5-point Wrinkle Severity Rating Scale (WSRS) score at 6 months was non-inferior to the contralateral Control Restylane treated side, where on this 5-point scale 1 has no measurable nasolabial fold, 2 has some fold, 3 has moderate fold, 4 has heavier moderate fold, and a 5 has deep to a very deep nasolabial fold. For this study only moderate nasolabial folds were included (i.e., 3 or 4), where subjects scored as 5 were excluded.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Event Reporting</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and Effectiveness of CosmetaLife at 3, 9 and 12 Months</measure>
    <time_frame>3, 9 and 12 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">145</enrollment>
  <condition>Facial Wrinkles</condition>
  <arm_group>
    <arm_group_label>CosmetaLife</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Test Article was given at start and two week follow up if necessary, up to a maximum dose of 2 cc to achieve optimal correction as determined by investigator.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Restylane</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control Article was given at start and two week follow up if necessary, up to a maximum dose of 2 cc to achieve optimal correction as determined by investigator.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CosmetaLife</intervention_name>
    <description>Dermal filler</description>
    <arm_group_label>CosmetaLife</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Restylane</intervention_name>
    <description>Dermal filler</description>
    <arm_group_label>Restylane</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients 18 years of age or older

          2. Patients with moderate nasolabial folds (3-4 WSRS scale)

          3. Patients willing to provide written informed consent for their participation in the
             study

          4. Patients willing to abstain from other facial cosmetic procedures through the 12
             month follow-up visit

        Exclusion Criteria:

          1. Patients with any aesthetic facial therapy within 6 months prior to

          2. Patients with an any reaction to the skin test

          3. Patients with a history of autoimmune disorder, lidocaine reactions, allergy to
             heparin, other severe or chronic allergies

          4. Patients with a current disease state that can effect the immunoresponse, or patients
             on immunosuppressive therapy

          5. Patients with an active infection of any kind, skin disease, connective tissue
             disorder

          6. Patients who are pregnant or lactating

          7. Patients enrolled in another investigational clinical trial
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David B. Masters, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Cosmeta™ Corp</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beauty Renewed</name>
      <address>
        <city>Tracy</city>
        <state>California</state>
        <zip>95376</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Atlantic Plastic and Reconstructive Surgery</name>
      <address>
        <city>Roswell</city>
        <state>Georgia</state>
        <zip>30076</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SkinCare Physicians of Chestnut Hill</name>
      <address>
        <city>Chestnut Hill</city>
        <state>Massachusetts</state>
        <zip>02467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cosmetic Care Center, LLC</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55424</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Clinical Study Center</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <lastchanged_date>June 22, 2011</lastchanged_date>
  <firstreceived_date>December 20, 2006</firstreceived_date>
  <firstreceived_results_date>March 4, 2011</firstreceived_results_date>
  <responsible_party>
    <name_title>David B. Masters/President</name_title>
    <organization>Cosmeta Corp, A Gel-Del Technologies Company</organization>
  </responsible_party>
  <keyword>Nasolabial folds</keyword>
  <keyword>Dermal filler</keyword>
  <keyword>Injectable dermal filler</keyword>
  <keyword>Soft tissue augmentation</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>CosmetaLife vs Restylane</title>
          <description>Split-face double blind study design used so each subject received each treatment followed by a two week touch up treatment, where no subject received more than 2cc of either CosmetaLife or Restylane treatment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="145"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="131"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CosmetaLife vs Restylane</title>
          <description>Split-face double blind study design used so each subject received each treatment followed by a two week touch up treatment, where no subject received more than 2cc of either CosmetaLife or Restylane treatment.</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="145"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="122"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="23"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="53.9" spread="10.0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="135"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="145"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Wrinkle Severity Rating Scale</title>
        <description>To determine if the mean change in the 5-point Wrinkle Severity Rating Scale (WSRS) score at 6 months was non-inferior to the contralateral Control Restylane treated side, where on this 5-point scale 1 has no measurable nasolabial fold, 2 has some fold, 3 has moderate fold, 4 has heavier moderate fold, and a 5 has deep to a very deep nasolabial fold. For this study only moderate nasolabial folds were included (i.e., 3 or 4), where subjects scored as 5 were excluded.</description>
        <time_frame>baseline and 6 months</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was intention to treat (ITT) and each subject received both CosmetaLife and Control (Restylane) injections into contralateral nasolabial folds, respectively. WSRS units (change from baseline analyzed)</population>
        <group_list>
          <group group_id="O1">
            <title>CosmetaLife</title>
            <description>CosmetaLife injected nasolabial fold side</description>
          </group>
          <group group_id="O2">
            <title>Restylane (Control)</title>
            <description>Restylane (Control) injected nasolabial fold contralateral side</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="140"/>
                  <measurement group_id="O2" value="140"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change in Wrinkle Severity Rating Scale</title>
            <description>To determine if the mean change in the 5-point Wrinkle Severity Rating Scale (WSRS) score at 6 months was non-inferior to the contralateral Control Restylane treated side, where on this 5-point scale 1 has no measurable nasolabial fold, 2 has some fold, 3 has moderate fold, 4 has heavier moderate fold, and a 5 has deep to a very deep nasolabial fold. For this study only moderate nasolabial folds were included (i.e., 3 or 4), where subjects scored as 5 were excluded.</description>
            <units>units on scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-0.94" spread="0.71"/>
                  <measurement group_id="O2" value="-1.07" spread="0.76"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The a priori hypothesis for statistical analysis was based on predetermined clinical relevance being set to a difference score between CosmetaLife and Control (Restylane) of -0.5. This clinical relevance was set to -0.5 because the observation scale used is not accurate below 0.5 differences. That is CosmetaLife needed to be greater than 0.5 less than Control (Restylane) in the treatment difference scores to be considered inferior.</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>The non-inferiority was tested.</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.13</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.60</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.0</ci_lower_limit>
            <ci_upper_limit>1.0</ci_upper_limit>
            <estimate_desc>The confidence interval is built around the mean difference of the two reporting groups.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Adverse Event Reporting</title>
        <time_frame>6 months</time_frame>
        <safety_issue>Yes</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety and Effectiveness of CosmetaLife at 3, 9 and 12 Months</title>
        <time_frame>3, 9 and 12 months</time_frame>
        <safety_issue>Yes</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>CosmetaLife</title>
        </group>
        <group group_id="E2">
          <title>Restylane (Control)</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="145"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="145"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Study results were presented and published at national meetings. Standard confidentiality agreements were signed by PIs for company confidential information.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. David B. Masters</name_or_title>
      <organization>Cosmeta, A Gel-Del Technolgies Company</organization>
      <phone>651 209-0707</phone>
      <email>dmasters@gel-del.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
